Journal of Clinical Oncology, Vol 15, 2866-2872, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival

F Graus, J Dalmou, R Rene, M Tora, N Malats, JJ Verschuuren, F Cardenal, N Vinolas, J Garcia del Muro, C Vadell, WP Mason, R Rosell, JB Posner and FX Real
Service of Neurology, Hospital Clinic i Provincial, Barcelona, Spain. graus@medicine.ub.es

PURPOSE: Anti-Hu antibodies (HuAb) recognize antigens expressed by neurons and small-cell lung cancer (SCLC). High titers of HuAb were initially reported in serum from patients with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/SN) and SCLC. Preliminary studies have indicated that some SCLC patients without PEM/SN harbor low titer of HuAb in their serum, and that the SCLC of these patients may grow more indolently. Based on these observations, we conducted a multicenter prospective study of SCLC patients without PEM/SN to determine the incidence and prognostic implications of HuAb. METHODS: Serum samples were collected at diagnosis of SCLC in 196 patients without PEM/SN. HuAb were determined by immunoblot of purified recombinant HuD antigen. RESULTS: HuAb were detected in 32 (16%) of the 196 patients. Of the 170 patients who received treatment for the tumor, 27 (16%) were HuAb positive. HuAb was associated with limited disease stage (59.3% v 38.6%; P = .047), complete response to therapy (55.6% v 19.6%; P < .001), and longer survival (14.9 v 10.2 months; P = .018). In a logistic regression analysis, HuAb status was an independent predictor of complete response induction. The probability of achieving a complete response was more than five times higher in HuAb-positive than in HuAb-negative patients (odds ratio, 5.4; 95% confidence interval, 1.71 to 16.89; P = .004). Cox multivariate analysis indicated that HuAb status was not independently associated with survival. CONCLUSION: The presence of HuAb at diagnosis of SCLC is a strong and independent predictor of complete response to treatment. This feature accounts for the association between HuAb and longer survival.

This article has been cited by other articles:

				S Watanabe, J Tanaka, T Ohta, H Yoshizawa, and F Gejyo Paraneoplastic neurological syndrome and polyglandular autoimmune syndrome type 2 in a case of small cell lung cancer Thorax, December 1, 2008; 63(12): 1118 - 1119. [Abstract] [Full Text] [PDF]

				L. Sabater, M. Titulaer, A. Saiz, J. Verschuuren, A. O. Gure, and F. Graus SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome Neurology, March 18, 2008; 70(12): 924 - 928. [Abstract] [Full Text] [PDF]

				P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]

				R. M. Mathew, R. Vandenberghe, A. Garcia-Merino, T. Yamamoto, J. C. Landolfi, M. R. Rosenfeld, J. E. Rossi, B. Thiessen, E. J. Dropcho, and J. Dalmau Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis Neurology, March 20, 2007; 68(12): 900 - 905. [Abstract] [Full Text] [PDF]

				J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]

				M Tschernatsch, E Stolz, M Strittmatter, M Kaps, and F Blaes Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1702 - 1706. [Abstract] [Full Text] [PDF]

				T. Martinu and A. S. Clay A 50-Year-Old Woman With Bilateral Vocal Cord Paralysis and Hilar Mass Chest, August 1, 2005; 128(2): 1028 - 1031. [Full Text] [PDF]

				A. Llado, P. Mannucci, A. F. Carpentier, S. Paris, Y. Blanco, A. Saiz, J. Y. Delattre, and F. Graus Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes Neurology, November 23, 2004; 63(10): 1947 - 1949. [Abstract] [Full Text] [PDF]

				F Graus, J Y Delattre, J C Antoine, J Dalmau, B Giometto, W Grisold, J Honnorat, P S. Smitt, C. Vedeler, J J G M Verschuuren, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1135 - 1140. [Abstract] [Full Text] [PDF]

				R. Linke, M. Schroeder, T. Helmberger, and R. Voltz Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis Neurology, July 27, 2004; 63(2): 282 - 286. [Abstract] [Full Text] [PDF]

				J H Rees Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii43 - ii50. [Full Text] [PDF]

				R. Darnell Tumor Immunity in Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2004; 22(5): 762 - 764. [Full Text] [PDF]

				S.E. Monstad, L. Drivsholm, A. Storstein, J.H. Aarseth, M. Haugen, B. Lang, A. Vincent, and C.A. Vedeler Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2004; 22(5): 795 - 800. [Abstract] [Full Text] [PDF]

				S. Vernino, B. P. O'Neill, R. S. Marks, J. R. O'Fallon, and D. W. Kimmel Immunomodulatory treatment trial for paraneoplastic neurological disorders Neuro-oncol, January 1, 2004; 6(1): 55 - 62. [Abstract] [PDF]

				G. Ragupathi, P. O. Livingston, C. Hood, J. Gathuru, S. E. Krown, P. B. Chapman, J. D. Wolchok, L. J. Williams, R. C. Oldfield, and W.-J. Hwu Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21 Clin. Cancer Res., November 1, 2003; 9(14): 5214 - 5220. [Abstract] [Full Text] [PDF]

				R. B. Darnell and J. B. Posner Paraneoplastic Syndromes Involving the Nervous System N. Engl. J. Med., October 16, 2003; 349(16): 1543 - 1554. [Full Text] [PDF]

				C. A Douglas and J. Ellershaw Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer Palliative Medicine, October 1, 2003; 17(7): 638 - 639. [Abstract] [PDF]

				F. Bernal, S. Shams'ili, I. Rojas, R. Sanchez-Valle, A. Saiz, J. Dalmau, J. Honnorat, P. Sillevis Smitt, and F. Graus Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease Neurology, January 28, 2003; 60(2): 230 - 234. [Abstract] [Full Text] [PDF]

				M. Sugita, M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, et al. Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer/Testis Antigens as Biomarkers in Lung Carcinoma Cancer Res., July 15, 2002; 62(14): 3971 - 3979. [Abstract] [Full Text] [PDF]

				F. Brichory, D. Beer, F. LeNaour, T. Giordano, and S. Hanash Proteomics-based Identification of Protein Gene Product 9.5 as a Tumor Antigen That Induces a Humoral Immune Response in Lung Cancer Cancer Res., November 1, 2001; 61(21): 7908 - 7912. [Abstract] [Full Text] [PDF]

				F. Graus, F. Keime-Guibert, R. Rene, B. Benyahia, T. Ribalta, C. Ascaso, G. Escaramis, and J. Y. Delattre Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients Brain, June 1, 2001; 124(6): 1138 - 1148. [Abstract] [Full Text] [PDF]

				N.-K. V. Cheung, H.-f. Guo, G. Heller, and I. Y. Cheung Induction of Ab3 and Ab3' Antibody Was Associated with Long-Term Survival after Anti-GD2 Antibody Therapy of Stage 4 Neuroblastoma Clin. Cancer Res., July 1, 2000; 6(7): 2653 - 2660. [Abstract] [Full Text]

				J. C. Darnell, M. L. Albert, and R. B. Darnell cdr2, a Target Antigen of Naturally Occurring Human Tumor Immunity, Is Widely Expressed in Gynecological Tumors Cancer Res., April 1, 2000; 60(8): 2136 - 2139. [Abstract] [Full Text]

				F. Blaes, M. Klotz, H. Huwer, U. Straub, G. Kalweit, K. Schimrigk, and H.-J. Schafers Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer Ann. Thorac. Surg., January 1, 2000; 69(1): 254 - 258. [Abstract] [Full Text] [PDF]

				F. Keime-Guibert, F. Graus, P. Broet, R. Rene, J. L. Molinuevo, C. Ascaso, and J. Y. Delattre Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor Neurology, November 1, 1999; 53(8): 1719 - 1719. [Abstract] [Full Text]

				J. J Verschuuren, M. Perquin, G. ten Velde, M. De Baets, P. v. B. Vriesman, and A. Twijnstra Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 353 - 357. [Abstract] [Full Text]

				P. A. Bunn Jr. Immune Therapy for Lung Cancer . Are We Getting Closer? Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 10 - 12. [Full Text]

				A. Ohwada, I. Nagaoka, F. Takahashi, S. Tominaga, and Y. Fukuchi DNA Vaccination against HuD Antigen Elicits Antitumor Activity in a Small-Cell Lung Cancer Murine Model Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 37 - 43. [Abstract] [Full Text]

				J. O. Dalmau and J. B. Posner Paraneoplastic Syndromes Arch Neurol, April 1, 1999; 56(4): 405 - 408. [Full Text] [PDF]

				A Saiz, J Dalmau, M H. Butler, Q Chen, J Y Delattre, P De Camilli, and F Graus Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma J. Neurol. Neurosurg. Psychiatry, February 1, 1999; 66(2): 214 - 217. [Abstract] [Full Text]

				N. Sodeyama, K. Ishida, K. A Jaeckle, L. Zhang, A. Azuma, M. Yamada, H. Mizusawa, and Y. Wada Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome J. Neurol. Neurosurg. Psychiatry, January 1, 1999; 66(1): 97 - 99. [Abstract] [Full Text]

				J. O. Dalmau and J. B. Posner Neurological Paraneoplastic Syndromes Neuroscientist, November 1, 1998; 4(6): 443 - 453. [PDF]